Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA

The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-posi...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2025-01
Main Authors: Taniguchi, Yoshihiko, Tamiya, Akihiro, Osuga, Mitsuo, Isa, Shun-Ichi, Nakamura, Keiichi, Mizumori, Yasuyuki, Shinohara, Tsutomu, Yanai, Hidetoshi, Nakatomi, Katsumi, Oki, Masahide, Mori, Masahide, Kuwako, Tomohito, Yamazaki, Koji, Shimada, Masahiro, Ando, Masahiko, Koh, Yasuhiro
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c184t-ff654c2bdb20f5888ec36568508e2a9543fdb5b6051107261029e8df93c82eee3
container_end_page
container_issue
container_start_page
container_title Investigational new drugs
container_volume
creator Taniguchi, Yoshihiko
Tamiya, Akihiro
Osuga, Mitsuo
Isa, Shun-Ichi
Nakamura, Keiichi
Mizumori, Yasuyuki
Shinohara, Tsutomu
Yanai, Hidetoshi
Nakatomi, Katsumi
Oki, Masahide
Mori, Masahide
Kuwako, Tomohito
Yamazaki, Koji
Shimada, Masahiro
Ando, Masahiko
Koh, Yasuhiro
description The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-positive lung cancers, focusing on differences in pretreatment co-occurring genetic alterations in circulating tumor DNA. This was a secondary analysis of the ELUCIDATOR study, a multicenter prospective observational study in Japan that assessed the mechanisms underlying resistance to osimertinib as a first-line treatment for advanced NSCLC with EGFR mutations. We compared the progression-free survival (PFS), overall survival (OS), and pretreatment co-occurring genetic alterations detected in plasma between patients with stages IVA (n = 83) and IVB disease (n = 84). Multivariate analysis of PFS and OS revealed that stage IVB was associated with a poor prognosis (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.36-3.04, p 
doi_str_mv 10.1007/s10637-024-01500-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153917549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3153917549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c184t-ff654c2bdb20f5888ec36568508e2a9543fdb5b6051107261029e8df93c82eee3</originalsourceid><addsrcrecordid>eNo9kc1u1TAQhS1ERS-FF2CBvGRjGMexYy-r0hakqpX4WUeOM74ySuyL7VTq-7DnIfpiJNzCZkYzOueMRh8hbzi85wDdh8JBiY5B0zLgEoCZZ2THZScYqFY9JzvgqmPKmO6UvCzlBwAI07UvyOnatBHK7Mivr9XukZUDuuCDo-jXat0DTZ6mEmbMNcQw0BBpzWjrjLGyaB9_3yO9vL76wual2lhpTJGV2U4TdbiWaYl76mx0mKl1LuUxrIua6GALTiEi3WPEuh60U8Vsa0ixbEdcyG6Z1nmTL3PK9OPt-Sty4u1U8PVTPyPfry6_XXxiN3fXny_Ob5jjuq3MeyVb1wzj0ICXWmt0QkmlJWhsrJGt8OMgBwWSc-gaxaExqEdvhNMNIooz8u6Ye8jp54Kl9nMo2z82YlpKL7gUhneyNau0OUpdTqVk9P0hh9nmh55Dv9Hpj3T6lU7_l06_md4-5S_DjON_yz8c4g_UZY5J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3153917549</pqid></control><display><type>article</type><title>Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA</title><source>Springer Nature</source><creator>Taniguchi, Yoshihiko ; Tamiya, Akihiro ; Osuga, Mitsuo ; Isa, Shun-Ichi ; Nakamura, Keiichi ; Mizumori, Yasuyuki ; Shinohara, Tsutomu ; Yanai, Hidetoshi ; Nakatomi, Katsumi ; Oki, Masahide ; Mori, Masahide ; Kuwako, Tomohito ; Yamazaki, Koji ; Shimada, Masahiro ; Ando, Masahiko ; Koh, Yasuhiro</creator><creatorcontrib>Taniguchi, Yoshihiko ; Tamiya, Akihiro ; Osuga, Mitsuo ; Isa, Shun-Ichi ; Nakamura, Keiichi ; Mizumori, Yasuyuki ; Shinohara, Tsutomu ; Yanai, Hidetoshi ; Nakatomi, Katsumi ; Oki, Masahide ; Mori, Masahide ; Kuwako, Tomohito ; Yamazaki, Koji ; Shimada, Masahiro ; Ando, Masahiko ; Koh, Yasuhiro</creatorcontrib><description>The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-positive lung cancers, focusing on differences in pretreatment co-occurring genetic alterations in circulating tumor DNA. This was a secondary analysis of the ELUCIDATOR study, a multicenter prospective observational study in Japan that assessed the mechanisms underlying resistance to osimertinib as a first-line treatment for advanced NSCLC with EGFR mutations. We compared the progression-free survival (PFS), overall survival (OS), and pretreatment co-occurring genetic alterations detected in plasma between patients with stages IVA (n = 83) and IVB disease (n = 84). Multivariate analysis of PFS and OS revealed that stage IVB was associated with a poor prognosis (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.36-3.04, p &lt; 0.001, HR: 2.35, 95% CI: 1.45-3.90, p &lt; 0.001, respectively). Pre-osimertinib treatment, significantly more TP53- (52.4% vs. 27.7%, p = 0.002), EGFR amplification- (58.3% vs. 23.2%, p &lt; 0.001), and MET amplification-positive cases (22.6% vs. 7.2%, p = 0.008) were found among stage IVB than among stage IVA or lower cases. Patients with EGFR-positive NSCLC in stage IVB exhibited significantly shorter PFS and OS than those in earlier stages when treated with first-line osimertinib. The prevalence of baseline TP53 mutations, EGFR amplification, and MET amplification in plasma were significantly higher in stage IVB cases, implicating them in the worse outcomes of this group.</description><identifier>ISSN: 0167-6997</identifier><identifier>ISSN: 1573-0646</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/s10637-024-01500-9</identifier><identifier>PMID: 39789369</identifier><language>eng</language><publisher>United States</publisher><ispartof>Investigational new drugs, 2025-01</ispartof><rights>2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c184t-ff654c2bdb20f5888ec36568508e2a9543fdb5b6051107261029e8df93c82eee3</cites><orcidid>0000-0001-6387-3683</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39789369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taniguchi, Yoshihiko</creatorcontrib><creatorcontrib>Tamiya, Akihiro</creatorcontrib><creatorcontrib>Osuga, Mitsuo</creatorcontrib><creatorcontrib>Isa, Shun-Ichi</creatorcontrib><creatorcontrib>Nakamura, Keiichi</creatorcontrib><creatorcontrib>Mizumori, Yasuyuki</creatorcontrib><creatorcontrib>Shinohara, Tsutomu</creatorcontrib><creatorcontrib>Yanai, Hidetoshi</creatorcontrib><creatorcontrib>Nakatomi, Katsumi</creatorcontrib><creatorcontrib>Oki, Masahide</creatorcontrib><creatorcontrib>Mori, Masahide</creatorcontrib><creatorcontrib>Kuwako, Tomohito</creatorcontrib><creatorcontrib>Yamazaki, Koji</creatorcontrib><creatorcontrib>Shimada, Masahiro</creatorcontrib><creatorcontrib>Ando, Masahiko</creatorcontrib><creatorcontrib>Koh, Yasuhiro</creatorcontrib><title>Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-positive lung cancers, focusing on differences in pretreatment co-occurring genetic alterations in circulating tumor DNA. This was a secondary analysis of the ELUCIDATOR study, a multicenter prospective observational study in Japan that assessed the mechanisms underlying resistance to osimertinib as a first-line treatment for advanced NSCLC with EGFR mutations. We compared the progression-free survival (PFS), overall survival (OS), and pretreatment co-occurring genetic alterations detected in plasma between patients with stages IVA (n = 83) and IVB disease (n = 84). Multivariate analysis of PFS and OS revealed that stage IVB was associated with a poor prognosis (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.36-3.04, p &lt; 0.001, HR: 2.35, 95% CI: 1.45-3.90, p &lt; 0.001, respectively). Pre-osimertinib treatment, significantly more TP53- (52.4% vs. 27.7%, p = 0.002), EGFR amplification- (58.3% vs. 23.2%, p &lt; 0.001), and MET amplification-positive cases (22.6% vs. 7.2%, p = 0.008) were found among stage IVB than among stage IVA or lower cases. Patients with EGFR-positive NSCLC in stage IVB exhibited significantly shorter PFS and OS than those in earlier stages when treated with first-line osimertinib. The prevalence of baseline TP53 mutations, EGFR amplification, and MET amplification in plasma were significantly higher in stage IVB cases, implicating them in the worse outcomes of this group.</description><issn>0167-6997</issn><issn>1573-0646</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNo9kc1u1TAQhS1ERS-FF2CBvGRjGMexYy-r0hakqpX4WUeOM74ySuyL7VTq-7DnIfpiJNzCZkYzOueMRh8hbzi85wDdh8JBiY5B0zLgEoCZZ2THZScYqFY9JzvgqmPKmO6UvCzlBwAI07UvyOnatBHK7Mivr9XukZUDuuCDo-jXat0DTZ6mEmbMNcQw0BBpzWjrjLGyaB9_3yO9vL76wual2lhpTJGV2U4TdbiWaYl76mx0mKl1LuUxrIua6GALTiEi3WPEuh60U8Vsa0ixbEdcyG6Z1nmTL3PK9OPt-Sty4u1U8PVTPyPfry6_XXxiN3fXny_Ob5jjuq3MeyVb1wzj0ICXWmt0QkmlJWhsrJGt8OMgBwWSc-gaxaExqEdvhNMNIooz8u6Ye8jp54Kl9nMo2z82YlpKL7gUhneyNau0OUpdTqVk9P0hh9nmh55Dv9Hpj3T6lU7_l06_md4-5S_DjON_yz8c4g_UZY5J</recordid><startdate>20250109</startdate><enddate>20250109</enddate><creator>Taniguchi, Yoshihiko</creator><creator>Tamiya, Akihiro</creator><creator>Osuga, Mitsuo</creator><creator>Isa, Shun-Ichi</creator><creator>Nakamura, Keiichi</creator><creator>Mizumori, Yasuyuki</creator><creator>Shinohara, Tsutomu</creator><creator>Yanai, Hidetoshi</creator><creator>Nakatomi, Katsumi</creator><creator>Oki, Masahide</creator><creator>Mori, Masahide</creator><creator>Kuwako, Tomohito</creator><creator>Yamazaki, Koji</creator><creator>Shimada, Masahiro</creator><creator>Ando, Masahiko</creator><creator>Koh, Yasuhiro</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6387-3683</orcidid></search><sort><creationdate>20250109</creationdate><title>Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA</title><author>Taniguchi, Yoshihiko ; Tamiya, Akihiro ; Osuga, Mitsuo ; Isa, Shun-Ichi ; Nakamura, Keiichi ; Mizumori, Yasuyuki ; Shinohara, Tsutomu ; Yanai, Hidetoshi ; Nakatomi, Katsumi ; Oki, Masahide ; Mori, Masahide ; Kuwako, Tomohito ; Yamazaki, Koji ; Shimada, Masahiro ; Ando, Masahiko ; Koh, Yasuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c184t-ff654c2bdb20f5888ec36568508e2a9543fdb5b6051107261029e8df93c82eee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taniguchi, Yoshihiko</creatorcontrib><creatorcontrib>Tamiya, Akihiro</creatorcontrib><creatorcontrib>Osuga, Mitsuo</creatorcontrib><creatorcontrib>Isa, Shun-Ichi</creatorcontrib><creatorcontrib>Nakamura, Keiichi</creatorcontrib><creatorcontrib>Mizumori, Yasuyuki</creatorcontrib><creatorcontrib>Shinohara, Tsutomu</creatorcontrib><creatorcontrib>Yanai, Hidetoshi</creatorcontrib><creatorcontrib>Nakatomi, Katsumi</creatorcontrib><creatorcontrib>Oki, Masahide</creatorcontrib><creatorcontrib>Mori, Masahide</creatorcontrib><creatorcontrib>Kuwako, Tomohito</creatorcontrib><creatorcontrib>Yamazaki, Koji</creatorcontrib><creatorcontrib>Shimada, Masahiro</creatorcontrib><creatorcontrib>Ando, Masahiko</creatorcontrib><creatorcontrib>Koh, Yasuhiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taniguchi, Yoshihiko</au><au>Tamiya, Akihiro</au><au>Osuga, Mitsuo</au><au>Isa, Shun-Ichi</au><au>Nakamura, Keiichi</au><au>Mizumori, Yasuyuki</au><au>Shinohara, Tsutomu</au><au>Yanai, Hidetoshi</au><au>Nakatomi, Katsumi</au><au>Oki, Masahide</au><au>Mori, Masahide</au><au>Kuwako, Tomohito</au><au>Yamazaki, Koji</au><au>Shimada, Masahiro</au><au>Ando, Masahiko</au><au>Koh, Yasuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>2025-01-09</date><risdate>2025</risdate><issn>0167-6997</issn><issn>1573-0646</issn><eissn>1573-0646</eissn><abstract>The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-positive lung cancers, focusing on differences in pretreatment co-occurring genetic alterations in circulating tumor DNA. This was a secondary analysis of the ELUCIDATOR study, a multicenter prospective observational study in Japan that assessed the mechanisms underlying resistance to osimertinib as a first-line treatment for advanced NSCLC with EGFR mutations. We compared the progression-free survival (PFS), overall survival (OS), and pretreatment co-occurring genetic alterations detected in plasma between patients with stages IVA (n = 83) and IVB disease (n = 84). Multivariate analysis of PFS and OS revealed that stage IVB was associated with a poor prognosis (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.36-3.04, p &lt; 0.001, HR: 2.35, 95% CI: 1.45-3.90, p &lt; 0.001, respectively). Pre-osimertinib treatment, significantly more TP53- (52.4% vs. 27.7%, p = 0.002), EGFR amplification- (58.3% vs. 23.2%, p &lt; 0.001), and MET amplification-positive cases (22.6% vs. 7.2%, p = 0.008) were found among stage IVB than among stage IVA or lower cases. Patients with EGFR-positive NSCLC in stage IVB exhibited significantly shorter PFS and OS than those in earlier stages when treated with first-line osimertinib. The prevalence of baseline TP53 mutations, EGFR amplification, and MET amplification in plasma were significantly higher in stage IVB cases, implicating them in the worse outcomes of this group.</abstract><cop>United States</cop><pmid>39789369</pmid><doi>10.1007/s10637-024-01500-9</doi><orcidid>https://orcid.org/0000-0001-6387-3683</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0167-6997
ispartof Investigational new drugs, 2025-01
issn 0167-6997
1573-0646
1573-0646
language eng
recordid cdi_proquest_miscellaneous_3153917549
source Springer Nature
title Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A57%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stage-specific%20efficacy%20of%20osimertinib%20in%20treatment-na%C3%AFve%20EGFR-mutant%20non-small%20cell%20lung%20cancer%20according%20to%20baseline%20genetic%20alterations%20in%20circulating%20tumor%20DNA&rft.jtitle=Investigational%20new%20drugs&rft.au=Taniguchi,%20Yoshihiko&rft.date=2025-01-09&rft.issn=0167-6997&rft.eissn=1573-0646&rft_id=info:doi/10.1007/s10637-024-01500-9&rft_dat=%3Cproquest_cross%3E3153917549%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c184t-ff654c2bdb20f5888ec36568508e2a9543fdb5b6051107261029e8df93c82eee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3153917549&rft_id=info:pmid/39789369&rfr_iscdi=true